MULTIPLE MYELOMA

Results of the phase II DREAMM-2 trial recently published in The Lancet Oncology showed that the investigational agent belantamab mafodotin induced response rates above 30% and had a manageable safety profile in patients with heavily pretreated multiple myeloma.

During a Targeted Oncology™ case-based peer perspectives live discussion, Ravi Vij, MD, MBA, professor, Department of Medicine, Oncology Division, Bone Marrow Tranplantation & Leukemia, Washington University School of Medicine in St. Louis spoke with a group of oncologists about best practices for treating patients with multiple myeloma. The ideas he presented were based on a real case of a male patient with multiple myeloma.

Transplant-Eligible Newly Diagnosed Multiple Myeloma

Outcomes in Newly Diagnosed Transplant-Ineligible Multiple Myeloma

The phase III BELLINI trial demonstrated translocation 11;14 and high BCL2 gene expression are predictive of response to treatment with the addition of venetoclax to bortezomib plus dexamethasone in patients with relapsed/refractory multiple myeloma, according to the findings presented at the 2019 ASH Annual Meeting.

A significant proportion of patients with transplant-ineligible newly diagnosed multiple myeloma alive and progression free after >3 years following treatment with daratumumab in addition to standard first-line therapy, according to updated safety and efficacy findings from the randomized ALCYONE study.

In the phase I CRB-402 study, patients with heavily pretreated relapsed/refractory multiple myeloma and minimal residual disease negativity had very good partial responses to the anti-BCMA CAR T cell therapy bb21217, according to updated results presented at the 2019 American Society of Hematology Annual Meeting.<br /> &nbsp;

&nbsp;In a&nbsp;<em>Targeted Oncology&nbsp;</em>case-based peer perspectives live discussion with a group of physicians, C. Ola Landgren, MD, PhD, reviewed several combination regimens used in the treatment of multiple myeloma. Landgren, chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, used the case of a 51-year-old man with standard-risk disease to highlight the benefits and drawbacks of each therapy strategy.